Clinical trials: Clinical Efficacy
Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.
- Trial name
- NCT06994650
- Testing
- HRS9531
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Primary Hypercholesterolemia
A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia
This is a randomized, double-blind, multi-center, therapeutic confirmatory, phase 3 trial to evaluate the efficacy and safety of CKD-391 and CKD-331 in patients with primary hypercholesterolemia
- Trial name
- NCT05657574
- Testing
- D377, CKD-331, D086
- Where
- South Korea
- Volunteers
- 228 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Tremor
A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
This multi-center, randomized, double-blinded, placebo-controlled, dose-range-finding clinical trial (with an optional Extension comprised of an Extension Double-blind (DB) Lead in Period followed by an Extension Open-label (OL)…
- Trial name
- Essential1 (NCT05021991)
- Testing
- 100 mg PRAX-944, 60 mg PRAX-944, Flexibly dosed 20 mg to 100 mg PRAX-944
- Where
- 39 sites in United States, Canada
- Volunteers
- 133 people
- Sponsor
- Praxis Precision Medicines
Aging
Neuramis® Volume Lidocaine Treatment in Patients With Loss of Mid-face Volume
The purpose of this study is to compare the safety and efficacy of Neuramis® Volume Lidocaine, which is a biomaterial prosthesis and graft, with Juvederm® Voluma® with Lidocaine, for the patients who need correction due to a…
- Trial name
- NCT02721368
- Testing
- Neuramis® Volume Lidocaine, Juvederm® Voluma® with Lidocaine
- Where
- South Korea
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Medy-Tox
LDL Cholesterol, Triglycerides
Safety and Efficacy of a Natural Health Product in Reducing Cholesterol and Triglyceride Levels.
The purpose of this study is to assess the safety and efficacy of a natural health product among participants with elevated LDL cholesterol and triglyceride levels.
- Trial name
- NCT01028274
- Testing
- Investigational Product 1, Investigational Product 2
- Where
- Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Nordic Pharma, USA
Hereditary Angioedema (HAE)
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II
The main aim of this study is to compare the number of HAE attacks occuring in persons using lanadelumab with the number of HAE attacks before lanadelumab treatment was started.
- Trial name
- ENABLE (NCT04130191)
- Where
- 19 sites in Austria, Germany and 5 more
- Volunteers
- 140 people
- Sponsor
- Shire
Cough
Evaluation of the Efficacy and Tolerability of ABO/MEG-B-09 in Children With Acute Cough
The present clinical trial will examine the use of ABO/MEG-B-09 syrup in children with acute cough as compared to a placebo syrup.
- Trial name
- ABOMEG (NCT01259674)
- Testing
- AboMeg-B-09
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- Aboca Spa Societa' Agricola
Gynecological Malignancies
A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic Malignancies
This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with recurrent or metastatic gynecologic malignancies.
- Trial name
- NCT06131450
- Testing
- BL-M07D1
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
General Anesthesia
Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia
To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous [IV] slow injection over 30 [±5] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection…
- Trial name
- NCT05478174
- Testing
- HSK3486, Propofol
- Where
- 23 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Haisco-USA Pharmaceuticals, Inc.
Ovarian Cancer, Cervix Cancer
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic Gynecologic Cancer, and obtain…
- Conditions
- Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer
- Trial name
- NCT06215950
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Psoriasis
Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis
This study aims to evaluate the efficacy and safety of Apremilast tablets in patients with psoriasis over 32 weeks, through a multicenter, single-arm, open-label, phase 4 clinical trial.
- Trial name
- NCT07190391
- Volunteers
- 425 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Vasomotor Syndrome
Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.
A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal…
- Trial name
- NCT06726850
- Testing
- GS1-144
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease
The primary purpose of the study is to assess if treatment with TML-6 for 52 weeks will be effective in slowing, stopping, or improving cognitive and functional decline in participants with early Alzheimer's Disease (AD) as…
- Trial name
- NCT07612150
- Testing
- TML-6
- Volunteers
- 210 people
- Sponsor
- Merry Life Biomedical Co., Ltd.
Dementia of the Alzheimer's Type
The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease
The primary purpose of this study is to evaluate the safety and the tolerability of NEUROSTEM®-AD (Human Umbilical Cord Blood Derived Mesenchymal Stem Cells) and to assess the maximum tolerated dose (MTD).
- Trial name
- NCT01297218
- Testing
- Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Medipost Co Ltd.
Advanced Solid Tumors
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in subjects with Advanced Solid Tumors, refractory or resistant to standard therapy…
- Trial name
- CSG-1827-101 (NCT06076291)
- Testing
- SG1827
- Where
- 6 sites in China
- Volunteers
- 19 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Arthritis, Rheumatoid, Healthy
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy
To evaluate the safety and tolerability of multiple doses of BI 655064 administered subcutaneously in healthy volunteers (HVs) and in rheumatoid arthritis (RA) patients.
- Trial name
- NCT01751776
- Testing
- BI 655064
- Where
- 25 sites in Czechia, Germany and 4 more
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder, Recurrent
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)
The purpose of this study is to evaluate the safety and efficacy of filorexant (MK-6096) versus placebo as adjunctive treatment for major depressive disorder (MDD), in participants who are partial responders to antidepressant…
- Trial name
- NCT01554176
- Testing
- Filorexant
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Foot Ulcer
The Purpose of This Study is to Assess Clinical Efficacy and Safety of Berovenal® Intended to Promote Treatment and to Expedite Chronic Diabetic Foot Ulcer Healing
The goal of this clinical investigation is to evaluate clinical efficacy of medical device Berovenal® intended to promote treatment and to expedite healing of chronic diabetic foot ulcer in male or female subjects aged 18-85…
- Trial name
- NCT06584617
- Testing
- Berovenal®, NU-GEL Hydrogel with Alginate
- Where
- 9 sites in Germany, Poland
- Volunteers
- 66 people
- Sponsor
- VULM s.r.o.
Pain
A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain
This Phase III pivotal efficacy study will assess efficacy and onset of pain relief of MFC51123 gel vs. placebo and MFC51123 gel vs.
- Trial name
- NCT02100670
- Testing
- 1% diclofenac sodium plus 3% menthol, 1% diclofenac sodium plus 0.09% menthol, 3% menthol
- Where
- 3 sites in Germany
- Volunteers
- 385 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-Cell Lymphoma
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
This Phase Ib/II study is a clinical trial to explore the efficacy and safety of BL-M08D1 for injection in combination with immunochemotherapy in patients with diffuse large B-cell lymphoma.
- Trial name
- NCT07818499
- Testing
- BL-M08D1, Rituximab, Gemcitabine Hydrochloride
- Where
- 2 sites in China
- Volunteers
- 204 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.